GENB Generate Biomedicines, Inc. - Common Stock
$16.90
Price · Aug 19, 2026
Fundamentals as of Aug 6, 2026
52W Range
$11–$18
82% of range
Analyst Rating
BUY
12 analysts
Price Target
$26
+52% upside
P/E (TTM)
—
ROE
—
Net Profit Margin
—
GENB Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$16.89
Market Cap
—
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$11 – $18
GENB Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
—
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
GENB
Peer Median
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
GENB
Peer Median
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
GENB
Peer Median
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
GENB
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
GENB
Peer Median
GENB Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
12 analysts
- Strong Buy 3 25.0%
- Buy 8 66.7%
- Hold 1 8.3%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
5 analysts · 2026-08-17
Median
$25.00
← Below all targets
$16.89
Low
$22.00
High
$30.00
Median target
$25.00
+48.0%
Mean target
$25.60
+51.5%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-0.28%
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| June 30, 2026 | $-0.52 | $-0.51 | -0.01% |
| March 31, 2026 | $-1.06 | $-0.51 | -0.55% |
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| GENB | — | — | — | — | — | — |
| VRDN | $3.17B | -7.7 | 23359.9% | -483.6% | -55.4% | — |
| STOK | $1.87B | -264.5 | 404.5% | -3.7% | -2.0% | — |
| ZBIO | $1.98B | -4.3 | 100.0% | -3777.4% | -156.8% | — |
| AGIO | $1.59B | -3.8 | 48.0% | -764.0% | -32.2% | — |
| TSHA | $1.57B | -16.2 | 17.3% | -1115.3% | -44.0% | — |
| DMRA | — | — | 38.3% | -17981.1% | -167.0% | — |
| SRPT | $2.26B | -3.0 | 15.6% | -32.5% | -57.1% | — |
| SNDX | $1.84B | -6.4 | 627.8% | -165.6% | -257.1% | — |
| ANAB | — | -105.4 | 157.0% | — | — | — |
| NTLA | $1.05B | -2.4 | 16.9% | -609.8% | -59.5% | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Balance Sheet 20
| Metric | Trend | 2025 |
|---|---|---|
| Cash & Equivalents | $122M | |
| Short-term Investments | $100M | |
| Prepaid Expense | $13M | |
| Current Assets | $234M | |
| PP&E (Net) | $29M | |
| PP&E (Gross) | $77M | |
| Accum. Depreciation | $48M | |
| Other Non-current Assets | $7M | |
| Total Assets | $330M | |
| Accounts Payable | $4M | |
| Current Liabilities | $82M | |
| Capital Leases | $51M | |
| Other Non-current Liabilities | $116.0K | |
| Total Liabilities | $142M | |
| Common Stock | $33.0K | |
| Retained Earnings | $-676M | |
| AOCI | $106.0K | |
| Stockholders' Equity | $-616M | |
| Liabilities + Equity | $330M | |
| Shares Outstanding | 33,116,957 |
Income Statement 15
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Revenue | $6M | $7M | $10M | $9M | |
| R&D Expense | $64M | $58M | $60M | $47M | |
| SG&A Expense | $14M | $14M | $11M | $10M | |
| Operating Expenses | $78M | $71M | $70M | $57M | |
| Operating Income | $-72M | $-64M | $-60M | $-48M | |
| Interest Income | $5M | $3M | $4M | $4M | |
| Other Non-op | $4M | $2M | $3M | $4M | |
| Pretax Income | $-67M | $-62M | $-57M | $-44M | |
| Income Tax | $53.0K | $28.0K | $44.0K | $56.0K | |
| Net Income | $-67M | $-61M | $-52M | $-42M | |
| EPS (Basic) | $-0.52 | $-1.07 | $-1.94 | $-1.62 | |
| EPS (Diluted) | $-0.52 | $-1.07 | $-1.94 | $-1.62 | |
| Shares (Basic) | 128,240,371 | 64,871,295 | 32,996,506 | 32,791,905 | |
| Shares (Diluted) | 128,240,371 | 64,871,295 | 32,996,506 | 32,791,905 | |
| EBITDA | $-72M | $-64M | · | · |
Balance Sheet 20
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $135M | $161M | · | · | |
| Short-term Investments | $322M | $356M | · | · | |
| Prepaid Expense | $13M | $19M | · | · | |
| Current Assets | $470M | $535M | · | · | |
| PP&E (Net) | $27M | $28M | · | · | |
| PP&E (Gross) | $82M | $79M | · | · | |
| Accum. Depreciation | $55M | $52M | · | · | |
| Other Non-current Assets | $9M | $5M | · | · | |
| Total Assets | $562M | $626M | · | · | |
| Accounts Payable | $6M | $8M | · | · | |
| Current Liabilities | $57M | $58M | · | · | |
| Capital Leases | $48M | $49M | · | · | |
| Other Non-current Liabilities | $0 | $0 | · | · | |
| Total Liabilities | $106M | $111M | · | · | |
| Common Stock | $128.0K | $128.0K | · | · | |
| Retained Earnings | $-805M | $-738M | · | · | |
| AOCI | $-129.0K | $24.0K | · | · | |
| Stockholders' Equity | $456M | $515M | · | · | |
| Liabilities + Equity | $562M | $626M | · | · | |
| Shares Outstanding | 128,269,428 | 128,192,484 | · | · |
Cash Flow 8
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| D&A | $3M | $3M | $3M | $3M | |
| Stock-based Comp | $8M | $6M | $5M | $5M | |
| Operating Cash Flow | $-58M | $-80M | $-49M | $-53M | |
| CapEx | $933.0K | $4M | $154.0K | $751.0K | |
| Investing Cash Flow | $33M | $-260M | $-17M | $76M | |
| Financing Cash Flow | $-579.0K | $379M | $-263.0K | $21M | |
| Net Change in Cash | $-25M | $39M | $-66M | $43M | |
| Free Cash Flow | · | $-84M | · | · |
Profitability 7
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Operating Margin | -1134.2% | -887.5% | · | · | |
| Net Margin | -1065.2% | -850.6% | · | · | |
| Pretax Margin | -1064.3% | -853.9% | · | · | |
| EBITDA Margin | -1134.2% | -887.5% | · | · | |
| ROA | -23.9% | -19.6% | · | · | |
| ROE | -29.5% | -23.9% | · | · | |
| ROIC | -15.7% | -12.5% | · | · |
Liquidity & Solvency 2
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Current Ratio | 8.3 | 9.2 | · | · | |
| Quick Ratio | 8.1 | 8.8 | · | · |
Efficiency 1
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | · |
Valuation (TTM) 3
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Market Cap | $2.16B | · | · | · | |
| P/B | 4.7 | · | · | · | |
| P / Tangible Book | 4.7 | · | · | · |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Company insiders 13 insiders · 6 officers · 8 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Michael Nally | Chief Executive Officer | March 4, 2026 P | 572,707 | 1 | 0 | $240,000 |
| Jason Silvers | President & CFO | Feb. 26, 2026 A | 1,000 | 3 | 0 | $32,000 |
| Laurie Anne Lee | Chief Medical Officer | Feb. 26, 2026 A | — | 0 | 0 | $0 |
| Beth Grous | Chief People Officer | Feb. 26, 2026 A | 300 | 1 | 0 | $4,800 |
| Gevorg Grigoryan | Chief Technology Officer | Feb. 26, 2026 A | — | 0 | 0 | $0 |
| Sean Martin | Chief Legal Officer & GC | Feb. 26, 2026 A | — | 0 | 0 | $0 |
| Stephane Bancel | Director | March 2, 2026 C | 724,160 | 0 | 0 | $0 |
| Paul Gray Parker | Director | Feb. 26, 2026 A | — | 0 | 0 | $0 |
| Rupert Vessey | Director | Feb. 26, 2026 A | — | 0 | 0 | $0 |
| Jane L Mendillo | Director | Feb. 26, 2026 A | 1,500 | 1 | 0 | $24,000 |
| Frances Arnold | Director | Feb. 26, 2026 A | — | 0 | 0 | $0 |
| Nancy A Simonian | Director | Feb. 26, 2026 A | — | 0 | 0 | $0 |
| Marsha Fanucci | Director | Feb. 26, 2026 A | — | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 10 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.02% | 18,122 SH | Aug. 8, 2026 | Daily |
| IWO · iShares Trust | 0.01% | 154,022 SH | Aug. 8, 2026 | Daily |
| IWM · iShares Trust | 0.01% | 605,342 SH | Aug. 8, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.01% | 140,478 SH | Aug. 8, 2026 | Daily |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.01% | 6,607 SH | Aug. 8, 2026 | Daily |
| IWN · iShares Trust | 0.01% | 65,437 SH | Aug. 8, 2026 | Daily |
| ISCB · iShares Trust | 0.01% | 1,115 SH | Aug. 8, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.00% | 296,479 SH | Aug. 8, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 816,876 SH | Aug. 8, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 2,078 SH | Aug. 8, 2026 | Daily |